Last Update: Jun 09, 2026 Non-interventional Study on the Use of ILARIS® (Canakinumab) Among Familial Mediterranean Fever and Still's Disease Patients Across Europe and Israel ClinicalTrials.gov Identifier: [NCT07517250](https://clinicaltrials.gov/ct2/show/NCT07517250) Novartis Reference Number:CACZ885G2005 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \\\[SJIA\\\] and adult-onset Still's disease \\\[AOSD\\\]) that received canakinumab for at least 6 months. Condition Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still Disease Overall Status Recruiting Number of Participants160 Start Date Mar 15, 2026 Completion Date Dec 03, 2026 Gender All Age(s) 1 Year - (Child, Adult, Older Adult) ## Eligibility Criteria Inclusion criteria: \* Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD). \* Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment. Exclusion criteria: • Patients Aged \\<2 Years (24 Months) at Index Date. Switzerland #### Novartis Recruiting Basel,Switzerland ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: